BioSpace News Archive

BridGene Biosciences, Inc. today announced that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC,

Genprex, Inc. today announced the Company’s participation in the following upcoming investor and industry conferences to be held in October 2022.

We share the concerns of many parents and caregivers about their inability to find pediatric/infant and children’s acetaminophen and ibuprofen products, and we understand the worries associated with this.

CNS Pharmaceuticals Inc. today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 18 new employees.

Traditional chemotherapies continue to demonstrate limited efficacy in drug-sensitive and drug-resistant solid tumors. InnovoTEX Inc. (InnovoTEX), an Austin -based pharmaceutical company, is developing next generation anti-cancer agents that localize to solid tumors and overcome resistance mechanisms with minimal side effects.

ParaPRO today announced that it will unveil Thought Leader AI – a pioneering medical education platform that enables healthcare practitioners to engage “live” with leading clinical experts on topics of public health – at the American Academy of Pediatrics (AAP) National Conference & Exhibition in Anaheim, CA, October 7-11, 2022.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce the dosing of the first patient in the therapeutic phase of its Phase I/II theranostic trial evaluating 64Cu/67Cu SAR-bisPSMA theranostic products in patients with metastatic, castrate-resistant prostate cancer (mCRPC).

Today, Health Canada authorized a second bivalent COVID-19 vaccine booster.

WallachBeth Capital LLC announced today that Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit.